719 related articles for article (PubMed ID: 19179469)
1. CBFbeta is critical for AML1-ETO and TEL-AML1 activity.
Roudaia L; Cheney MD; Manuylova E; Chen W; Morrow M; Park S; Lee CT; Kaur P; Williams O; Bushweller JH; Speck NA
Blood; 2009 Mar; 113(13):3070-9. PubMed ID: 19179469
[TBL] [Abstract][Full Text] [Related]
2. The role of CBFbeta in AML1-ETO's activity.
Park S; Speck NA; Bushweller JH
Blood; 2009 Sep; 114(13):2849-50. PubMed ID: 19779050
[No Abstract] [Full Text] [Related]
3. Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation.
Thiel VN; Giaimo BD; Schwarz P; Soller K; Vas V; Bartkuhn M; Blätte TJ; Döhner K; Bullinger L; Borggrefe T; Geiger H; Oswald F
Leukemia; 2017 Nov; 31(11):2491-2502. PubMed ID: 28360416
[TBL] [Abstract][Full Text] [Related]
4. Structure of the AML1-ETO NHR3-PKA(RIIα) complex and its contribution to AML1-ETO activity.
Corpora T; Roudaia L; Oo ZM; Chen W; Manuylova E; Cai X; Chen MJ; Cierpicki T; Speck NA; Bushweller JH
J Mol Biol; 2010 Sep; 402(3):560-77. PubMed ID: 20708017
[TBL] [Abstract][Full Text] [Related]
5. The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity.
Liu Y; Cheney MD; Gaudet JJ; Chruszcz M; Lukasik SM; Sugiyama D; Lary J; Cole J; Dauter Z; Minor W; Speck NA; Bushweller JH
Cancer Cell; 2006 Apr; 9(4):249-60. PubMed ID: 16616331
[TBL] [Abstract][Full Text] [Related]
6. The AML1/ETO(MTG8) and AML1/Evi-1 leukemia-associated chimeric oncoproteins accumulate PEBP2beta(CBFbeta) in the nucleus more efficiently than wild-type AML1.
Tanaka K; Tanaka T; Kurokawa M; Imai Y; Ogawa S; Mitani K; Yazaki Y; Hirai H
Blood; 1998 Mar; 91(5):1688-99. PubMed ID: 9473235
[TBL] [Abstract][Full Text] [Related]
7. Transforming activity of AML1-ETO is independent of CBFbeta and ETO interaction but requires formation of homo-oligomeric complexes.
Kwok C; Zeisig BB; Qiu J; Dong S; So CW
Proc Natl Acad Sci U S A; 2009 Feb; 106(8):2853-8. PubMed ID: 19202074
[TBL] [Abstract][Full Text] [Related]
8. The acute myeloid leukemia associated AML1-ETO fusion protein alters the transcriptome and cellular progression in a single-oncogene expressing in vitro induced pluripotent stem cell based granulocyte differentiation model.
Tijchon E; Yi G; Mandoli A; Smits JGA; Ferrari F; Heuts BMH; Wijnen F; Kim B; Janssen-Megens EM; Schuringa JJ; Martens JHA
PLoS One; 2019; 14(12):e0226435. PubMed ID: 31869378
[TBL] [Abstract][Full Text] [Related]
9. An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice.
Grisolano JL; O'Neal J; Cain J; Tomasson MH
Proc Natl Acad Sci U S A; 2003 Aug; 100(16):9506-11. PubMed ID: 12881486
[TBL] [Abstract][Full Text] [Related]
10. A tool compound targeting the core binding factor Runt domain to disrupt binding to CBFβ in leukemic cells.
Oo ZM; Illendula A; Grembecka J; Schmidt C; Zhou Y; Esain V; Kwan W; Frost I; North TE; Rajewski RA; Speck NA; Bushweller JH
Leuk Lymphoma; 2018 Sep; 59(9):2188-2200. PubMed ID: 29249175
[TBL] [Abstract][Full Text] [Related]
11. TEL-AML1 preleukemic activity requires the DNA binding domain of AML1 and the dimerization and corepressor binding domains of TEL.
Morrow M; Samanta A; Kioussis D; Brady HJ; Williams O
Oncogene; 2007 Jun; 26(30):4404-14. PubMed ID: 17237815
[TBL] [Abstract][Full Text] [Related]
12. Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO's activity.
Liu Y; Chen W; Gaudet J; Cheney MD; Roudaia L; Cierpicki T; Klet RC; Hartman K; Laue TM; Speck NA; Bushweller JH
Cancer Cell; 2007 Jun; 11(6):483-97. PubMed ID: 17560331
[TBL] [Abstract][Full Text] [Related]
13. Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia.
Engel ME; Hiebert SW
Cancer Treat Res; 2010; 145():127-47. PubMed ID: 20306249
[TBL] [Abstract][Full Text] [Related]
14. Dominant negative effects of the AML1/ETO fusion oncoprotein.
Fenske TS; Pengue G; Graubert TA
Cell Cycle; 2005 Jan; 4(1):33-6. PubMed ID: 15611635
[TBL] [Abstract][Full Text] [Related]
15. Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity.
Park S; Chen W; Cierpicki T; Tonelli M; Cai X; Speck NA; Bushweller JH
Blood; 2009 Apr; 113(15):3558-67. PubMed ID: 19204326
[TBL] [Abstract][Full Text] [Related]
16. Core-binding factor beta (CBFbeta), but not CBFbeta-smooth muscle myosin heavy chain, rescues definitive hematopoiesis in CBFbeta-deficient embryonic stem cells.
Miller JD; Stacy T; Liu PP; Speck NA
Blood; 2001 Apr; 97(8):2248-56. PubMed ID: 11290585
[TBL] [Abstract][Full Text] [Related]
17. The role of CBFbeta in AML1-ETO's activity.
Kwok C; Zeisig BB; Dong S; So CW
Blood; 2010 Apr; 115(15):3176-7. PubMed ID: 20395424
[No Abstract] [Full Text] [Related]
18. Defining the oncogenic function of the TEL/AML1 (ETV6/RUNX1) fusion protein in a mouse model.
Fischer M; Schwieger M; Horn S; Niebuhr B; Ford A; Roscher S; Bergholz U; Greaves M; Löhler J; Stocking C
Oncogene; 2005 Nov; 24(51):7579-91. PubMed ID: 16044150
[TBL] [Abstract][Full Text] [Related]
19. TEL-AML1 promotes development of specific hematopoietic lineages consistent with preleukemic activity.
Morrow M; Horton S; Kioussis D; Brady HJ; Williams O
Blood; 2004 May; 103(10):3890-6. PubMed ID: 14726384
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal.
Zhao X; Chen A; Yan X; Zhang Y; He F; Hayashi Y; Dong Y; Rao Y; Li B; Conway RM; Maiques-Diaz A; Elf SE; Huang N; Zuber J; Xiao Z; Tse W; Tenen DG; Wang Q; Chen W; Mulloy JC; Nimer SD; Huang G
Blood; 2014 Mar; 123(11):1729-38. PubMed ID: 24449215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
